Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three drugs—lidocaine, epinephrine, and sufentanil—used primarily in regional (spinal or epidural) anesthesia for surgical procedures.\n- **Lidocaine** is an amide-type local anesthetic that blocks sodium channels on neuronal cell membranes, preventing nerve impulse conduction and resulting in loss of sensation at the site of administration. It is also classified as a class Ib antiarrhythmic agent[4][5].\n- **Epinephrine** (adrenaline) acts as a vasoconstrictor by stimulating alpha-adrenergic receptors, reducing local blood flow to prolong the effect of lidocaine and decrease systemic absorption. This helps maintain anesthesia at the target site and reduces bleeding[5].\n- **Sufentanil** is a potent synthetic opioid analgesic that acts primarily on mu-opioid receptors to provide profound analgesia. It is used as an adjunct to enhance pain control during anesthesia[1][6].\n\nThe combination aims to optimize surgical anesthesia by providing rapid onset (from lidocaine), prolonged duration (with epinephrine), and strong analgesia (from sufentanil). This regimen has been studied for use in spinal or epidural anesthesia for procedures such as cesarean section or lower limb surgery[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + epinephrine + sufentanil.